Avenue Therapeutics
menu
  • About
    • Management Team
    • Board of Directors
  • Pipeline
  • Publications
  • Investors
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Events
  • Contact Us
    • Careers
      • Email Alerts

Press Releases

Investors

Investors

  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Oct 11, 2022

Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering

Oct 06, 2022

Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering

Sep 22, 2022

Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA

Feb 15, 2022

Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

Feb 15, 2022

Avenue Therapeutics Stock Trading Halted Today

Dec 15, 2021

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

Dec 12, 2021

Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock

Nov 29, 2021

Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022

Nov 17, 2021

Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option

Nov 12, 2021

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Privacy
  • Disclaimer
  • Contact Us


twitter icon linked-in icon
Website Design, Maintenance and Hosting by Tidal Media Group
Copyright ©2023 Avenue Therapeutics.

logo